重症筋無力症(Myasthenia Gravis):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Myasthenia Gravis - Pipeline Review, H2 2014
◆商品コード:GMDHC5819IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年12月10日
◆ページ数:93
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における重症筋無力症(Myasthenia Gravis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・重症筋無力症(Myasthenia Gravis)の概要
・重症筋無力症(Myasthenia Gravis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・重症筋無力症(Myasthenia Gravis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・重症筋無力症(Myasthenia Gravis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・重症筋無力症(Myasthenia Gravis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Myasthenia Gravis – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Myasthenia Gravis – Pipeline Review, H2 2014’, provides an overview of the Myasthenia Gravis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Myasthenia Gravis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Myasthenia Gravis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myasthenia Gravis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Myasthenia Gravis Overview 8
Therapeutics Development 9
Pipeline Products for Myasthenia Gravis – Overview 9
Pipeline Products for Myasthenia Gravis – Comparative Analysis 10
Myasthenia Gravis – Therapeutics under Development by Companies 11
Myasthenia Gravis – Therapeutics under Investigation by Universities/Institutes 13
Myasthenia Gravis – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Myasthenia Gravis – Products under Development by Companies 17
Myasthenia Gravis – Products under Investigation by Universities/Institutes 18
Myasthenia Gravis – Companies Involved in Therapeutics Development 19
Alexion Pharmaceuticals, Inc. 19
Alnylam Pharmaceuticals, Inc. 20
Astellas Pharma Inc. 21
Biokine Therapeutics Ltd. 22
CuraVac, Inc. 23
Cytokinetics, Inc. 24
GlaxoSmithKline plc 25
Grifols, S.A. 26
HanAll Biopharma Co., Ltd. 27
Neurotune AG 28
Pfizer Inc. 29
Regenesance BV 30
Toleranzia AB 31
Myasthenia Gravis – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ALN-CC5 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
belimumab – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BKT-130 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CK-2066260 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
eculizumab – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GL-2045 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HL-161 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
immune globulin (human) – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NT-1654 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Recombinant Coversin – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Recombinant Protein for Myasthenia Gravis – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Regenemab – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
tacrolimus – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
tirasemtiv – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Vaccine for Myasthenia Gravis – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Vaccine for Myasthenia Gravis – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Myasthenia Gravis – Recent Pipeline Updates 64
Myasthenia Gravis – Dormant Projects 79
Myasthenia Gravis – Discontinued Products 80
Myasthenia Gravis – Product Development Milestones 81
Featured News & Press Releases 81
Sep 16, 2014: Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases 81
Aug 01, 2014: European Commission Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG) 82
Jun 17, 2014: FDA Grants Orphan Drug Designation to Soliris (eculizumab) for the Treatment of Patients with Myasthenia Gravis 83
Jun 09, 2014: Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases 83
Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 85
Apr 24, 2014: Toleranzia supported by VINNOVA 86
Dec 08, 2013: New Alnylam Pre-clinical Results on ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases, Demonstrate up to 98% Serum C5 Knockdown and up to 94% Inhibition of Hemolytic Activity in Non-Human Primates 86
Jun 20, 2013: Alnylam Scientists Present Preclinical Data With ALN-CC5 For Treatment Of Complement-mediated Diseases 89
Mar 21, 2013: Cytokinetics Announces Presentation Of Phase IIA Clinical Trial Data Of Tirasemtiv In Patients With Myasthenia Gravis 90
Mar 13, 2013: Cytokinetics Announces Presentation Of Phase IIa Trial Data On Tirasemtiv At 65th AAN Annual Meeting 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

[List of Tables]
Number of Products under Development for Myasthenia Gravis, H2 2014 9
Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals, Inc., H2 2014 19
Myasthenia Gravis - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 20
Myasthenia Gravis - Pipeline by Astellas Pharma Inc., H2 2014 21
Myasthenia Gravis - Pipeline by Biokine Therapeutics Ltd., H2 2014 22
Myasthenia Gravis - Pipeline by CuraVac, Inc., H2 2014 23
Myasthenia Gravis - Pipeline by Cytokinetics, Inc., H2 2014 24
Myasthenia Gravis - Pipeline by GlaxoSmithKline plc, H2 2014 25
Myasthenia Gravis - Pipeline by Grifols, S.A., H2 2014 26
Myasthenia Gravis - Pipeline by HanAll Biopharma Co., Ltd., H2 2014 27
Myasthenia Gravis - Pipeline by Neurotune AG, H2 2014 28
Myasthenia Gravis - Pipeline by Pfizer Inc., H2 2014 29
Myasthenia Gravis - Pipeline by Regenesance BV, H2 2014 30
Myasthenia Gravis - Pipeline by Toleranzia AB, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Myasthenia Gravis Therapeutics - Recent Pipeline Updates, H2 2014 64
Myasthenia Gravis - Dormant Projects, H2 2014 79
Myasthenia Gravis - Discontinued Products, H2 2014 80

[List of Figures]
Number of Products under Development for Myasthenia Gravis, H2 2014 9
Number of Products under Development for Myasthenia Gravis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Products, H2 2014 16
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Top 10 Targets, H2 2014 33
Number of Products by Stage and Top 10 Targets, H2 2014 34
Number of Products by Top 10 Mechanism of Actions, H2 2014 35
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 36
Number of Products by Top 10 Routes of Administration, H2 2014 37
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 38
Number of Products by Top 10 Molecule Types, H2 2014 39
Number of Products by Stage and Top 10 Molecule Types, H2 2014 40

【掲載企業】

Alexion Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Astellas Pharma Inc.
Biokine Therapeutics Ltd.
CuraVac, Inc.
Cytokinetics, Inc.
GlaxoSmithKline plc
Grifols, S.A.
HanAll Biopharma Co., Ltd.
Neurotune AG
Pfizer Inc.
Regenesance BV
Toleranzia AB

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[重症筋無力症(Myasthenia Gravis):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆